Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Valesca P Retèl"'
Autor:
Eline M J Lammers, Josée M Zijlstra, Valesca P Retèl, Berthe M P Aleman, Flora E van Leeuwen, Annelies Nijdam
Publikováno v:
JMIR Research Protocols, Vol 13, p e55601 (2024)
BackgroundHodgkin lymphoma (HL) occurs at young ages, with the highest incidence between 20 and 40 years. While cure rates have improved to 80%-90% over the past decades, survivors of HL are at substantial risk of late treatment–related complicatio
Externí odkaz:
https://doaj.org/article/96733ba3b3c14f89b8567a50ad39b2a8
Autor:
John Haanen, Marco Donia, Troels Holz Borch, Inge Marie Svane, Bastiaan Nuijen, Cynthia Nijenhuis, Valesca P Retèl, Tine Monberg, Renske M T ten Ham, Maartje W Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Melanie Lindenberg, Wim van Harten
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Introduction In a multicenter, open-label randomized phase 3 clinical trial conducted in the Netherlands and Denmark, treatment with ex vivo-expanded tumor-infiltrating lymphocytes (TIL-NKI/CCIT) from autologous melanoma tumor compared with ipilimuma
Externí odkaz:
https://doaj.org/article/861ff4b06089417c8f45e19942083ea2
Autor:
Anne M May, Maike G Sweegers, Wim H Van Harten, Martijn M Stuiver, Alina Vrieling, Richard P Meijer, Antoine G van der Heijden, Wim G Groen, Emine Akdemir, Helene Rundqvist, Annemarie M Leliveld-Kors, Vera C Rutten, Evert L Koldewijn, Siebe D Bos, Carl J Wijburg, Tom A T Marcelissen, Bart C Bongers, Valesca P Retèl
Publikováno v:
BMJ Open, Vol 13, Iss 3 (2023)
Introduction Radical cystectomy (RC) is the standard treatment for patients with non-metastatic muscle-invasive bladder cancer, as well as for patients with therapy refractory high-risk non-muscle invasive bladder cancer. However, 50–65% of patient
Externí odkaz:
https://doaj.org/article/6898d199b52a41e6bfef5e52ecb207a2
Autor:
Ann-Jean C C Beck, Jacobien M Kieffer, Valesca P Retèl, Lydia F J van Overveld, Robert P Takes, Michiel W M van den Brekel, Wim H van Harten, Martijn M Stuiver
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0226077 (2019)
INTRODUCTION:Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the req
Externí odkaz:
https://doaj.org/article/ba9466165a874f7cb8ec5e9d2f77ab0f
Autor:
Joost G.E. Verbeek, Leyla Azarang, Luis E. Pilli, Vincent M.T. de Jong, Agnes Jager, Sabine C. Linn, Valesca P. Retèl, Wim H. van Harten
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD). In
Externí odkaz:
https://doaj.org/article/20428d92475a4fe8be71426416fab27c
Autor:
Astrid Kramer, Marjolein J. E. Greuter, Suzanna J. Schraa, Geraldine R. Vink, Jillian Phallen, Victor E. Velculescu, Gerrit A. Meijer, Daan van den Broek, Miriam Koopman, Jeanine M. L. Roodhart, Remond J. A. Fijneman, Valesca P. Retèl, Veerle M. H. Coupé
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk patients and undertreatment of low-risk patients. Postoperative circulating
Externí odkaz:
https://doaj.org/article/df477bb60b4f45289ac535ad731952c5
Autor:
Anna Miquel-Cases, Valesca P Retèl, Bianca Lederer, Gunter von Minckwitz, Lotte M G Steuten, Wim H van Harten
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0154386 (2016)
PURPOSE:Guiding response to neoadjuvant chemotherapy (guided-NACT) allows for an adaptative treatment approach likely to improve breast cancer survival. In this study, our primary aim is to explore the expected cost-effectiveness of guided-NACT using
Externí odkaz:
https://doaj.org/article/46ed5e2776ac42d3891498fa2052cc81
Autor:
Joost G. E. Verbeek, Vincent M. T. de Jong, Hanna M. Wijnja, Agnes Jager, Sabine C. Linn, Valesca P. Retèl, Wim H. van Harten
Publikováno v:
BMC Cancer, 23(1):26. BioMed Central Ltd.
BMC cancer, 23(1):26. BioMed Central
BMC cancer, 23(1):26. BioMed Central
Background High-dose chemotherapy with autologous stem cell rescue (HDCT) is a promising treatment for patients with stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer. Clinical effectiveness and cost-effectiveness are c
Autor:
Astrid Kramer, Ed Schuuring, Daan C.L. Vessies, Paul van der Leest, Maartje J. Geerlings, Pim Rozendal, Mirthe Lanfermeijer, Theodora C. Linders, Léon C. van Kempen, Remond J.A. Fijneman, Marjolijn J.L. Ligtenberg, Gerrit A. Meijer, Daan van den Broek, Valesca P. Retèl, Veerle M.H. Coup
Publikováno v:
Journal of molecular diagnostics, 25(1), 36-45. ELSEVIER SCIENCE INC
Journal of Molecular Diagnostics, 25, 36-45
Journal of Molecular Diagnostics, 25, 1, pp. 36-45
Journal of Molecular Diagnostics, 25, 36-45
Journal of Molecular Diagnostics, 25, 1, pp. 36-45
Contains fulltext : 291298.pdf (Publisher’s version ) (Open Access) Circulating tumor DNA (ctDNA) is a promising new biomarker with multiple potential applications in cancer care. Estimating total cost of ctDNA testing is necessary for reimbursemen
Autor:
Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen
Publikováno v:
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125
Item does not contain fulltext BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 tr